← Back to Search

Stress Management Therapy for Triple Negative Breast Cancer

N/A
Recruiting
Led By Samilia Obeng-Gyasi, MD, MPH
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Untreated newly diagnosed triple negative breast cancer
Age >=18 years
Must not have
Individuals not able to speak and understand English
Male
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if a 10-wk stress reduction program can help patients with triple negative breast cancer reduce stress and address their health-related social needs.

Who is the study for?
This trial is for adults over 18 with newly diagnosed, untreated triple negative breast cancer at stages I-III. It's not open to prisoners, men, certain ethnic groups, those who can't speak and understand English, or anyone with stage IV breast cancer or a history of DCIS or invasive breast cancer.
What is being tested?
The study tests a ten-week biobehavioral stress reduction program that includes relaxation techniques, coping strategies, problem-solving skills enhancement and social support for patients with triple negative breast cancer. It also assesses the participants' health-related social needs.
What are the potential side effects?
Since this trial focuses on stress management rather than medication or medical procedures, traditional side effects are not expected. However, participants may experience emotional discomfort when discussing personal issues during therapy sessions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with triple negative breast cancer and have not received any treatment.
Select...
I am 18 years old or older.
Select...
My cancer is at an early to mid-stage (I-III).

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot speak or understand English.
Select...
I am male.
Select...
My breast cancer is at stage IV.
Select...
I have a history of breast cancer or DCIS.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Acceptability of the biobehavioral intervention
Feasibility biobehavioral intervention
Tolerability of the biobehavioral intervention
Secondary study objectives
Completeness of biomarkers collected to calculate allostatic load

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Health Services Research (stress management therapy)Experimental Treatment4 Interventions
Patients receive biobehavioral stress reduction intervention while on study. Patients undergo blood specimen collection at baseline and follow up and have their medical records reviewed.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 3
~2030
Stress Management Therapy
2018
N/A
~30

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
342 Previous Clinical Trials
293,167 Total Patients Enrolled
23 Trials studying Breast Cancer
2,902 Patients Enrolled for Breast Cancer
Samilia Obeng-Gyasi, MD, MPHPrincipal InvestigatorOhio State University Comprehensive Cancer Center

Media Library

Biobehavioral Stress Reduction Intervention Clinical Trial Eligibility Overview. Trial Name: NCT05677802 — N/A
Breast Cancer Research Study Groups: Health Services Research (stress management therapy)
Breast Cancer Clinical Trial 2023: Biobehavioral Stress Reduction Intervention Highlights & Side Effects. Trial Name: NCT05677802 — N/A
Biobehavioral Stress Reduction Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05677802 — N/A
~13 spots leftby Dec 2025